Following a recent proxy battle with activist investor Sarissa Capital and facing decreased revenue, the company will restructure in an attempt to maintain cash flow.
Weeks after CEO departure, Illumina starts laying off R&D staff
In its quarterly report, Takeda noted the post-operative gastrointestinal dysfunction drug it was developing with Theravance didn’t meet its endpoints.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix